Nexavar действа като забавя скоростта на растежа на раковите клетки и като прекъсва кръвоснабдяването, поддържащо растежа на раковите клетки.
The effectiveness of Nexavar in hepatocellular carcinoma has been studied in one main study including 602 patients, and its effectiveness in advanced renal cell carcinoma has been studied in one main study including 903 patients in whom one previous anti-cancer treatment had stopped working.